Change in Deferred Revenue
Regeneron Pharmaceuticals Change in Deferred Revenue increased by 3312.9% to $99.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 462.7%, from $17.70M to $99.60M. Over 3 years (FY 2021 to FY 2025), Change in Deferred Revenue shows an upward trend with a -24.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong future demand and cash inflow, while a decrease suggests revenue recognition from previously collected cash.
Detailed definition
This represents the net change in cash received from customers for goods or services that have not yet been delivered or...
Peer comparison
Common in long-term contract businesses like LNG; peers with similar business models often show significant deferred revenue balances.
change_in_deferred_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $78.80M | -$6.40M | -$49.00M | $9.50M | $100.20M | -$17.70M | -$35.90M | -$14.50M | $45.30M | $43.00M | $116.90M | $89.10M | $43.00M | $0.00 | $17.70M | -$142.90M | $76.60M | -$3.10M | $99.60M |
| QoQ Change | — | -108.1% | -665.6% | +119.4% | +954.7% | -117.7% | -102.8% | +59.6% | +412.4% | -5.1% | +171.9% | -23.8% | -51.7% | -100.0% | — | -907.3% | +153.6% | -104.0% | >999% |
| YoY Change | — | — | — | — | +27.2% | -176.6% | -477.9% | -114.5% | +355.9% | — | +425.6% | +714.5% | -5.1% | -100.0% | -84.9% | -260.4% | +78.1% | — | +462.7% |
Change in Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's change in deferred revenue?
- Regeneron Pharmaceuticals (REGN) reported change in deferred revenue of $99.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's change in deferred revenue changed year-over-year?
- Regeneron Pharmaceuticals's change in deferred revenue increased by 462.7% year-over-year, from $17.70M to $99.60M.
- What is the long-term trend for Regeneron Pharmaceuticals's change in deferred revenue?
- Over 3 years (2021 to 2025), Regeneron Pharmaceuticals's change in deferred revenue has grown at a -24.5% compound annual growth rate (CAGR), from -$120.20M to -$51.70M.
- What does change in deferred revenue mean?
- The net change in payments received from customers for services not yet provided.